This pandemic required communication among specialists and primary care. In this COVID-19 panel, faculty will team up to discuss the most pressing and frequently asked questions about this disease and its complications.
With ever-changing information on the 2019 novel coronavirus (COVID-19), it is hard to keep the facts straight! There’s new information about vaccines daily but it can be challenging to keep up. In additions there is new data on emerging treatment options. Join Drs. Charles Vega and Ty Gluckman as they team up live to discuss the most recent vaccine efficacy data, the recommendations for boosters, and the new efficacy and safety data for molnupiravir.
With ever-changing information on the 2019 novel coronavirus (COVID-19), it is hard to keep the facts straight! There’s new information about vaccines daily but it can be challenging to keep up. Join Drs. Charles Vega and Ty Gluckman as they team up live to discuss vaccines for children 5-11 years old, and vaccine-associated Myocarditis.
An Interactive Learning ExperienceThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com
Clinicians must be up to date on the latest guidelines for COVID-19. The proposed self-assessment initiative utilizes an adaptive learning platform to correct confidently held misinformation, covering the latest COVID-19 testing recommendations, Emergency Use Authorizations for treatment of mild to moderate COVID-19, predominant variants, and patient prioritization strategies.
This pandemic requires communication among specialists and primary care clinicians. In this COVID-19 panel, expert faculty will team up to discuss the most pressing and frequently asked questions about the disease and its complications.
Guest: Alan M. Ehrlich, MD, FAAFPMusic Credit: Richard Onorato
Most cases of COVID-19 will resolve without interventions, but some patients are at high risk for complications. Several treatment options for high-risk patients are now available to help prevent the need for hospitalization. Join us to review a recent large, randomized trial evaluating fluvoxamine as a treatment for high-risk patients who were diagnosed with COVID-19.
Guest: Jillian Joseph, MSPAS, PA-CMusic Credit: Richard Onorato
Get answers to your questions on COVID-19 infection in children. Listen to this podcast to review outcomes and potential risk factors associated with acute COVID-19 infection in this population. Finally, learn the status of immunizations for children younger than 5 years of age.
Guest: Robert A. Baldor, MD, FAAFPMusic Credit: Richard Onorato
The FDA’s recent emergency use authorization (EUA) for oral agents to treat COVID-19 means that primary care providers (PCPs) will be on the frontline of treating patients with COVID-19. Therefore, PCPs must understand who is eligible for such treatments and how to prescribe them. We will discuss the results of the recent FDA EUA for Pfizer’s Paxlovid and Merck’s molnupiravir antiviral agents and give you the information you need to confidently prescribe them.
Since March 2020 we have been in the middle of a pandemic related to SARS-CoV2, an infection derived from the movement of a non-human coronavirus into humans. Emerging (and re-emerging) infections occur due to many factors, including population growth, travel, movement out of rural areas and more. Learn about what emerging infections to be on the lookout for during this 60 minute session.